These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36937113)

  • 1. The role of flumazenil in generalised anxiety disorder: a pilot naturalistic open-label study with a focus on treatment resistance.
    Gallo AT; Addis S; Martyn V; Ramanathan H; Wilkerson GK; Bennett KS; Hood SD; Stampfer H; Hulse GK
    Ther Adv Psychopharmacol; 2023; 13():20451253231156400. PubMed ID: 36937113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Management of Generalised Anxiety Disorder with Low-Dose Continuous Infusions of Flumazenil: A Case Series.
    Gallo AT; Addis S; Martyn V; Ramanathan H; Wilkerson GK; Hood SD; Stampfer H; Hulse GK
    Behav Sci (Basel); 2022 Nov; 12(11):. PubMed ID: 36354407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: the FACTOID feasibility study.
    Gould RL; Wetherell JL; Serfaty MA; Kimona K; Lawrence V; Jones R; Livingston G; Wilkinson P; Walters K; Novere ML; Howard RJ
    Health Technol Assess; 2021 Sep; 25(54):1-150. PubMed ID: 34542399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
    Carter NJ; McCormack PL
    CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological treatments as defined by the National Institute for Health and Care Excellence guidelines.
    Buszewicz M; Cape J; Serfaty M; Shafran R; Kabir T; Tyrer P; Clarke CS; Nazareth I
    Health Technol Assess; 2017 Aug; 21(45):1-138. PubMed ID: 28853392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating generalized anxiety disorder using complementary and alternative medicine.
    McPherson F; McGraw L
    Altern Ther Health Med; 2013; 19(5):45-50. PubMed ID: 23981404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flumazenil Pretreatment Reduces Mefenamic Acid-Induced Central Nervous System Toxicity in Mice.
    Jarrar Q; Ayoub R; Jarrar Y; Aburass H; Goh KW; Ardianto C; Ming LC; Moshawih S; Alfaqih H
    J Integr Neurosci; 2023 Jul; 22(4):104. PubMed ID: 37519168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptance and commitment therapy for late-life treatment-resistant generalised anxiety disorder: a feasibility study.
    Gould RL; Wetherell JL; Kimona K; Serfaty MA; Jones R; Graham CD; Lawrence V; Livingston G; Wilkinson P; Walters K; Le Novere M; Leroi I; Barber R; Lee E; Cook J; Wuthrich VM; Howard RJ
    Age Ageing; 2021 Sep; 50(5):1751-1761. PubMed ID: 33852722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability.
    Montgomery S; Emir B; Haswell H; Prieto R
    Curr Med Res Opin; 2013 Oct; 29(10):1223-30. PubMed ID: 23808960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the Precipitation of Anxiety Symptoms Associated with Bolus Doses of Flumazenil a Barrier to Its Use at Low Continuous Doses in Benzodiazepine Withdrawal?
    Gallo A; MacDonald T; Bennett K; Basso-Hulse G; Hulse G
    J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care.
    Lenox-Smith AJ; Reynolds A
    Br J Gen Pract; 2003 Oct; 53(495):772-7. PubMed ID: 14601352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders.
    Glue P; Neehoff SM; Medlicott NJ; Gray A; Kibby G; McNaughton N
    J Psychopharmacol; 2018 Jun; 32(6):663-667. PubMed ID: 29561204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.
    Rosenthal M
    J Clin Psychiatry; 2003 Oct; 64(10):1245-9. PubMed ID: 14658975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET measurement of "GABA shift" in the rat brain: A preclinical application of bolus plus constant infusion paradigm of [
    Kim W; Park HS; Moon BS; Lee BC; Kim SE
    Nucl Med Biol; 2017 Feb; 45():30-34. PubMed ID: 27886620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term open-label chamomile (Matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder.
    Keefe JR; Mao JJ; Soeller I; Li QS; Amsterdam JD
    Phytomedicine; 2016 Dec; 23(14):1699-1705. PubMed ID: 27912871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder.
    Montgomery S; Chatamra K; Pauer L; Whalen E; Baldinetti F
    Br J Psychiatry; 2008 Nov; 193(5):389-94. PubMed ID: 18978320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial.
    Mohamed S; Osatuke K; Aslam M; Kasckow J
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):201-9. PubMed ID: 17062320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review.
    Nevitt SJ; Marson AG; Weston J; Tudur Smith C
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD001769. PubMed ID: 30091458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.